FDA Clearance Tracker · P890064-S029
DIGENE HC2 HIGH RISK HPV DNA TEST AND DIGENE HC2 HPV DNA TEST
Last checked: Nov 20, 2026Latest source record: Apr 14, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Apr 14, 2014
Approved
Time to decision
242 days
Received Aug 15, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P890064-S029
- Device name
- DIGENE HC2 HIGH RISK HPV DNA TEST AND DIGENE HC2 HPV DNA TEST
- Applicant
- Qiagen Gaithersburg, Inc.
- Applicant location
- Germantown, MD
- Received
- Aug 15, 2013
- Decided
- Apr 14, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P890064
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A MANUFACTURING SITE LOCATED AT QIAGEN INCORPORATED IN GERMANTOWN, MARYLAND.
Source documents
Other decisions for Qiagen Gaithersburg, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.